MyomoMYO -0.96%55 EBIT per Share is $-0.34 as of Mar. 2026. GuruFocus rates MYO with a GF Score™ of 55/100 and a GF Value™ of $3.13 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Myomo ranks better than 83.77% on this metric.
Myomo's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.34.
During the past 3 years, the average EBIT per Share Growth Rate was 39.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 43.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Myomo's EBIT per Share or its related term are showing as below:
MYO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -8.4 Med: 55.4 Max: 59.1
Current: 39
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Myomo was 59.10% per year. The lowest was -8.40% per year. And the median was 55.40% per year.
MYO's 3-Year EBIT Growth Rate is ranked better than 83.77% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs MYO: 39.00
Myomo's EBIT for the
three
months ended in Mar. 2026 was $-3.16 Mil.
Myomo (AMEX:MYO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Myomo EBIT per Share Related Terms
Myomo EBIT per Share Historical Data
* Premium members only.
The historical data trend for Myomo's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myomo (MYO) has a EBIT per Share of $-0.34 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Myomo and its competitors. According to the industry distribution chart, Myomo ranks #112 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 16.2%.
Is Myomo's EBIT per Share too high?
Myomo's current EBIT per Share is $-0.34. Based on the distribution chart, Myomo ranks #112 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Myomo has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's EBIT per Share compare to FOFA and ELUT?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #112 out of 690 companies for EBIT per Share. This places Myomo in the top 16% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Myomo and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myomo's current EBIT per Share is $-0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.13, compared to a current price of $1.03 — trading 67.1% below its estimated fair value. The current EBIT per Share is $-0.34. Myomo's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Myomo (MYO), the current EBIT per Share is $-0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myomo (MYO) Overvalued in 2026?
Based on GuruFocus' analysis, Myomo stock appears to be undervalued.
The current stock price of $1.03 is trading 67.1% below its estimated GF Value™ of $3.13.
GuruFocus considers Myomo to be Possible Value Trap.
Key valuation signals for MYO:
EBIT per Share: $-0.34
GF Value™: $3.13 vs. price of $1.03 (67.1% below fair value)
No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
55GF Score
Get the complete analysis for MYO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYO has been successfully added to your 
